Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Parturients, Depressive Symptoms, Esketamine, Dexmedetomidine, Intranasal Administration, Postpartum Depression

In brief

Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.

Key facts

Study ID
NCT07639099
Run by
Peking University First Hospital
People needed
164
Starts
2026-06-01
Expected to finish
2029-12-01
Last updated by the study team
2026-06-15

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.